Q-omics provides the consensus-scored PPP1R21 profile across patient tissues and cancer cell-line models. PPP1R21 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PPP1R21 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, PPP1R21 protein abundance shows 22,580 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, HNSC, and LUAD as cancer lineages where PPP1R21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPP1R21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPP1R21 survival associations across molecular data types. PPP1R21 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPP1R21 RNA expression–survival associations across cancer types. High PPP1R21 expression shows unfavorable associations in ACC, LIHC and BLCA, but favorable associations in KIRC, THCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PPP1R21 RNA expression.
This table summarizes PPP1R21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PPP1R21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPP1R21 shows lower tumor expression in KICH, KIRC, UCEC and LUAD and higher tumor expression in HNSC and CHOL. The HNSC box plot shows higher PPP1R21 RNA expression in tumor versus normal tissue (log2 FC = +0.695, t-test p < 0.001).
This table shows molecular features associated with PPP1R21 in patient tissues and cancer cell lines. In patient samples, PPP1R21 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PPP1R21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LUNG_NSCLC_LUAD.
